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Introduction
The study of the genetics of complex diseases is now
advancing rapidly as new genes are being discovered that
are involved in susceptibility for a variety of diseases.
However, more impressive is the fact that the identification
of the genes and the polymorphisms involved in
susceptibility is opening new avenues of study. The best
example at hand is the recent identification of a
polymorphism in the PDCD1 (programmed cell death 1)
gene as a susceptibility factor for systemic lupus
erythematosus, coding for the immunoreceptor PD-1 [1].
The polymorphism identified, named PD1.3 and whose
allele A is strongly associated with the disease, is so far
the only polymorphism within the PDCD1 gene that can
provide a functional explanation for the susceptibility
related to this gene. Furthermore, the same allele A was
associated to diabetes type 1 [2]. Association was also
identified with rheumatoid arthritis [3].
The PD1.3 polymorphism is located in the fourth intron of
the PDCD1 gene [1]. Within the fourth intron there is a
sequence of 160 base pairs enriched in binding sites for
various transcription factors important in hematopoiesis,
suggesting that this element might act as a regulatory
enhancer. Importantly, the regulator element is not
conserved in the mouse (ME Alarcón-Riquelme and L
Prokunina, unpublished data), suggesting that the
regulation of PD-1 is different in both species. The
polymorphism associated with human lupus changed a
common G nucleotide to an A nucleotide, thereby
disrupting a binding site for what seemed to be the
RUNX1 transcription factor. The binding was tested on a
simple band-shift assay (electrophoretic mobility-shift
assay) with specific antibodies, experiments that
supported the notion that the associated allelic variant did
not allow binding of a protein complex and that the
complex included, among other proteins, RUNX1 [1],
thereby providing a functional explanation for the genetic
association.
The potential role of RUNX1 was underscored by the
recent finding by two groups describing polymorphisms
strongly associated with psoriasis and rheumatoid arthritis
[4,5], both of which, even if present in completely different
genes, also disrupted binding sites for what seemed to be
RUNX1. For rheumatoid arthritis [5], the authors
investigated a complete 3-centimorgan genomic segment
from human chromosome 5q31 that included the cytokine
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Abstract
Recent studies investigating the genetic susceptibility of systemic lupus erythematosus, rheumatoid
arthritis and psoriasis have revealed a potential role for the RUNX proteins in the development of
autoimmune disease. A new pathway of disease pathogenesis opens new avenues of research with
thousands of questions that remain to be answered. In this review I attempt to propose how the RUNX
proteins might be involved in these diseases and review current knowledge on this very interesting trio
of transcription factors that was previously only suspected to be involved in cancer.
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gene cluster, a cluster previously also linked to rheumatoid
arthritis [6] and Crohn’s disease [7] with a high-resolution
single-nucleotide polymorphism genotyping. The search
led to the pinning down of a single polymorphism
disrupting the RUNX1-binding site within the organic
cation transporter gene SLC22A4 [5]. Furthermore, and
providing a stronger case, the authors identified a
preliminary association of rheumatoid arthritis with the
RUNX1 gene itself, with a SNP located in intron 6 of
RUNX1 in chromosome 21q22. This is an interesting test
and a first attempt to define disease pathways and identify
susceptibility genes or susceptibility effects that might be
epistatic, additive or independent.
Similarly, the psoriasis study analyzed a region previously
identified by linkage in sibling pairs, and by thorough
haplotype analysis narrowed it down to a single
polymorphism (having excluded the remaining nine that
showed association out of hundreds studied) that also
disrupted a binding site for RUNX1 [4]. This time the
polymorphism was found in a non-coding intergenic
region between SLC9A3R1, a solute carrier gene, and the
N-acetyltransferase gene NAT9. It was impossible for the
authors to determine which of the two genes was the
target for the effects of the polymorphism, but SLC9A3R1
was found expressed in skin and in T cells [4].
Thus genetics, in three studies, has led to the
identification of at least four new genes potentially
involved in autoimmunity. In the center, the runt-domain
family of transcription factors seem to be potential major
regulators.
In the studies described, the authors performed mobility
assays and transfection experiments with which they
could show the allelic effect of the polymorphisms on
gene expression in reporter assays and their effect by co-
transfection of RUNX1. In spite of these experiments, the
possibility still remains that it is not RUNX1 the
transcription factor that is binding to the altered sites, but
that it might also be any of its sisters, RUNX2 or RUNX3.
The reason for this is that the consensus sequence that is
the binding site for the runt family of transcription factors
is the same for all three members, so the artificial use of
oligonucleotides or even co-transfection does not fully
resolve the issue. At this point, only chromatin immuno-
precipitation can directly provide an answer; with this
technique we can analyze specifically which of the three
transcription factors is binding in vivo to the target
sequence in the gene of interest.
However, it is clear that the RUNX proteins have a role not
yet understood in autoimmune diseases. What could this
role be? The runt-domain family of transcription factors is
involved in several diseases and acts on target genes in a
variety of tissues [8]. The three members, RUNX1, RUNX2
and RUNX3, can be expressed in the same cell, but their
binding to the consensus sequence is dependent on their
relative levels and their affinity for the adaptor CBFβ (core
binding factor β), with which all of the three can
heterodimerize [9,10]. It is clear that each of the three
RUNX proteins has different roles and that their tissue
expression is different, but they might overlap in some of
their functions. The runt domain is highly conserved down
to Drosophila [11]. Indeed, the first member of the family
of runt-domain transcription factors was the Drosophila
regulatory gene runt, shown to determine segmentation
patterns during embryogenesis and later found to have
functions in sex determination and neurogenesis [12]. A
second member, named lozenge, is required for cell
patterning in the eye and for hematopoiesis. In humans the
three genes are located in completely different
chromosomes. RUNX1 is located in human chromosome
21, RUNX2 is located in chromosome 6, and RUNX3 is
located in chromosome 1.
The runt-domain family
Generally, the runt-domain transcription factors are
considered to be repressors. Most of the studies
performed so far in humans include the RUNX1 protein
previously known as AML1a. AML1a was originally
identified because it is frequently involved in mutations
and translocations associated with acute myeloid leukemia
[13]. The Aml1a-related translocations have provided an
important source of study for the function of RUNX1 as a
repressor as well as the proteins that have been found to
be forming a fusion protein in various of the translocations.
The t(8;21) translocation results in a fusion protein
between RUNX1 and ETO, a zinc-finger protein that is
most probably a transcription factor acting as a nuclear
repressor [14–16]. Further translocations have been
identified, including the t(12;21) translocation resulting in
the fusion of RUNX1 with TEL [17–19], also a
transcription factor, and a t(16;21) translocation in which
RUNX1 fuses with MTG16 (myeloid transforming gene-
related protein 1) or the t(3;21) translocation involving the
Evi-1 gene [20,21].
Thus, studies on the translocations and the resulting
fusion proteins that disrupt RUNX1 or the fusion partner
suggest a dominant-negative effect for RUNX1. Indeed,
mice made deficient for RUNX1 lack development of their
hematopoietic system in a dominant fashion [22]. In
humans, haploinsufficiency due to structural mutations in
RUNX1 leads to familial thrombocytopenia and a greatly
increased risk for the development of acute myeloid
leukemia [13,23,24]. As an observation, within a family
described for RUNX1 haploinsufficiency, an individual with
the mutation had rheumatoid arthritis [23].
Deficiency in RUNX2 (also called AML3) leads to bone
malformation and boneless mice; RUNX2 is therefore of171
major importance in skeletal development and in
osteoblast and chondrocyte development [25,26],
although recent evidence shows that RUNX1 might also
be involved in skeletal development [27] and has been
found expressed in the skin and other epithelial tissues
[27]. Mice made deficient for RUNX3 develop gastric
cancer, and these studies have also shown that RUNX3 is
involved in the development of basal root ganglia [28,29].
However, there has never been any previous evidence that
the RUNX proteins are involved in autoimmunity, either in
mouse models or in human studies. The main reasons for
this lack of evidence are that the recently produced
deficiency models have strong dominant loss-of-function
effects, and that RUNX1, the only one of the three to have
been studied extensively in humans, has been related to
leukemias.
This suggests that the effects of the RUNX proteins in
autoimmunity are much more subtle and are possibly
readable only at the level of specific cellular
compartments; this is in line with what is expected for
complex diseases.
The RUNX proteins in immune development
Interestingly, conditional cellular models and the use of
retroviral vectors have permitted the study of the RUNX
proteins in more detail, although still in the mouse, and
have provided evidence for the importance of the RUNX
proteins in the immune system.
Both RUNX1 and RUNX3 are required in T cell develop-
ment. It has recently been reported that RUNX1 is
required for active repression in CD4–CD8– thymocytes,
whereas RUNX3 is required for establishing epigenetic
silencing in cytotoxic lineage thymocytes [30]. RUNX3-
deficient cytotoxic T cells, but not T helper (Th) cells, were
reported to have defective responses to antigen,
suggesting that RUNX proteins could have critical
functions in lineage specification and in homeostasis of
CD8-lineage T lymphocytes. In addition, RUNX1 and
RUNX3 have been found to regulate the expression of
CD4 during CD8 lineage commitment [31].
It has also been observed that RUNX1 inhibits the
differentiation of naive CD4+ T cells into the Th2 lineage
[32]. This is done through direct influence on the main
transcription factor regulating Th2 development, GATA-3.
Another interesting and recent finding is that the lack of
RUNX3 in a mouse model results in eosinophilic airway
inflammation. Interestingly, RUNX3 was found to be
expressed in mouse mature dendritic cells and to mediate
dendritic cell responses to transforming growth factor
(TGF)-β [33]. The authors observed that in the RUNX3
knockout mice, maturation of dendritic cells was
accelerated when induced with lipopolysaccharide or
without induction, and showed an increased efficiency in
stimulating T cells. It is also interesting that the skin
epidermis of the RUNX3 knockout mice lacked epidermal
Langerhans cells but not dendritic epidermal T cells.
RUNX3 is known to mediate lymphoid and myeloid activity
of CD11a through direct interaction with its promoter, and
the RUNX3 knockout mice showed aberrant expression of
CD11a, CD11b and CD11c, the β2-integrins.
The findings revealed by the RUNX3 knockout mouse
might provide us with some ideas about how the
involvement of the RUNX proteins could be explained in
systemic lupus erythematosus, rheumatoid arthritis and
psoriasis. It would be interesting to investigate the effect
of the RUNX3 deficiency in another genetic backgound, to
test whether a ‘permissible’ background would allow the
development of an autoimmune phenotype.
Regulation of targets of the RUNX proteins
As mentioned previously, the RUNX proteins are
transcription factors or repressors for various target
genes, and their action might be modulated through many
different signaling pathways exerting their affect at various
cellular levels as well as at various developmental levels.
For example, RUNX2 is essential for skeletal development.
It has been shown that RUNX2 is essential in osteoblast
differentiation. RUNX2 regulates osteocalcin, osteo-
protegerin, TGF-β receptor 1, osteopontin and collagenase
3, among others, in osteoblasts [8,34,35]. Furthermore,
RUNX2 is known to regulate the expression of osteopontin,
collagenase 3 and vascular endothelial growth factor
(VEGF) in chondrocytes [7,36–38].
A possibility exists that susceptibility to rheumatoid
arthritis and part of the development of the disease might
be related to the activity of RUNX2 in these tissues and its
effect on some of the target genes, many of which, such
as osteopontin [34,35], collagenase 3 [39] and VEGF
[37], have been shown to have altered expression or have
been otherwise implicated in rheumatoid arthritis. VEGF, a
mediator of angiogenesis, has been correlated with
disease severity and has also been found to be involved
with psoriasis [40].
Both RUNX1 and RUNX3 have mainly been found to
regulate genes expressed in lymphoid and myeloid cells.
Among the targets of RUNX1 are the B cell-specific
tyrosine kinase BLK, the T-cell antigen receptor α, β, γ and
δ chains, CD3 and granulocyte/macrophage colony-
stimulating factor in lymphoid cells. The genes encoding
myeloperoxidase, complement receptor 1 and p21Waf1/Cip1
have been shown to be among the target genes for
RUNX1 in myeloid cells. Of these, p21 has been found to
have a role in systemic lupus erythematosus [41] in animal
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models, and there is extensive literature on the role of
complement receptor 1 (previously known as the C3b
receptor or CD35) in lupus and even in drug-induced
systemic lupus erythematosus [42,43]. No targets have
been thoroughly investigated for RUNX3. A more
extensive list of target genes can be found in [8].
Regulation of the RUNX proteins
Little is known about the regulation of the RUNX proteins
and the pathways in which they are controlled. Most of our
knowledge comes from studies of RUNX2.
Structurally, the RUNX genes are very similar. In mammals,
it seems that the gene encoding RUNX3 might have been
the one from which the other two evolved [11]. Each of
the RUNX genes is transcribed from two promoters [8].
For instance, RUNX2 is regulated distinctively in different
tissues. Activator protein 1 regulates RUNX2 through
binding to FosB in osteoblasts, whereas non-fimbrial
adhesin (NFA)-1 regulates RUNX2 in non-osseous cells
[44–46].
RUNX2 is also regulated by TGF-β, and regulation by
TGF-β is dependent on the cellular compartment [47].
TGF-β represses RUNX2 in an osteosarcoma cell line,
whereas it induces RUNX2 in a myoblast precursor cell
line. The effects of TGF-β on RUNX2 seem to be
mediated by the Smad factors [48]. Other proteins that
regulate RUNX2 are the bone morphogenetic proteins,
members of the TGF-β superfamily [47]. These are also
known to exert their effects through recruitment of the
Smad proteins, in which case other Smads are involved.
Tumor necrosis factor-α and FGF have also been shown
to regulate RUNX2 [49]. In particular, tumor necrosis
factor-α inhibits RUNX2.
It is interesting that retinoids bring about increased
expression of the three RUNX proteins. Similarly, vitamin
D3 also augmented the expression of the RUNX proteins
in myeloid leukemia cells. It has recently been shown that
estrogen (estradiol) enhances RUNX2 activity without
changing RUNX2 expression or DNA binding affinity but
through direct interaction with estrogen receptor α.
Glucocorticoids have been found to inhibit RUNX2
activity. All previous work suggests that RUNX2 might be
very important in bone regeneration, bone formation and
repair, and it is of particular interest when considering the
susceptibility to response to treatment of patients with
rheumatoid arthritis or to disease severity and damage.
Very little is known about the regulation of the other RUNX
proteins, and it is evident that these have profound effects
at numerous levels of cellular activities.
At present it is unclear how the RUNX proteins exert their
effects and how their aberrant function leads to
autoimmunity and inflammation. However, a new chapter
of investigation has now been opened that might lead to
many surprises [50].
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